Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 83

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 83
---
 will have an exercise price of $3.01 per share and will be exercisable beginning on the effective date of the Warrant Stockholder Approval. The Series C-1 Warrants will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series C-2 Warrants will expire on the twenty-four-month anniversary of the Warrant Stockholder Approval.

<div align='center'>50</div>

While we intend to promptly seek Warrant Stockholder Approval, there is no guarantee that the Warrant Stockholder Approval will ever be obtained. If we are unable to obtain the Warrant Stockholder Approval, the Warrants may have no value. The market price for our common stock has been volatile and may continue to fluctuate or may decline significantly in the future. An active, liquid and orderly market for our common stock may not be sustained, which could depress the trading price of our common stock or cause it to continue to be highly volatile or subject to wide fluctuations. Some of the factors that could negatively affect our share price or result in fluctuations in the price or trading volume of our common stock include, among other things:

| ● | the commencement, enrollment, or results of our current and future preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector; |

| ● | regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process; |

| ● | manufacturing, supply or distribution delays or shortages; |

| ● | our ability to identify and successfully acquire or in-license new product candidates on acceptable terms; |

| ● | FDA, state or international regulatory actions, including actions on regulatory applications any of our product candidates; |

| ● | legislative or regulatory changes; |

| ● | judicial pronouncements interpreting laws and regulations; |

| ● | changes in government programs; |

| ● | announcements of new products, services or technologies, commercial relationships, acquisitions or other events by us or our competitors; |

| ● | market conditions in the pharmaceutical and biotechnology sectors; |

| ● | fluctuations in stock market prices and trading volumes of similar companies; |

| ● | changes in accounting principles; |

| ● | litigation or public concern about the safety of our product candidates or similar product candidates; |

| ● | sales of large blocks of our common stock, including sales by our executive officers, directors and significant shareholders; and |

| ● | our ability to obtain additional financing to